It is expected that soon Zydus Cadila’s vaccine based on indigenous technology will be available to the people. This vaccine will also be given to children above 12 years of age. Zydus Cadila has completed its trial and after that had applied to the Drugs Controller General of India (DCGI) for its emergency use.
The Ahmedabad-based pharmaceutical firm had on July 1, requested emergency use approval for ZyCoV-D, its three-dose Covid shot – the world’s first Plasmid DNA vaccine.
It will, however, be a few more days before the country’s drug regulator Drugs Controller General of India (DCGI) gives it emergency use authorisation, sources told ANI on Monday.
The affidavit further submitted that vaccination is the Centre’s topmost priority and all efforts are being made to achieve 100 percent vaccination in the shortest time possible, keeping the availability of vaccine doses in mind.
The data has shown that ZyCoV-D is safe for children in the age group of 12 to 18 years, said the company, which is planning to manufacture 100-120 million doses of the vaccine annually.
The study was carried out “during the peak of the second wave of Covid-19 (in India), reaffirming the vaccine’s efficacy against the new mutant strains, especially the Delta variant,” Zydus said in a statement.
Once Zydus receives approval, ZyCoV-D would become the fifth anti-Covid vaccine authorised for use in India, after AstraZeneca and Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Sputnik V that is being developed by Russia’s Gamaleya Institute and Moderna.